Developing Multicellular Therapies for Severe Cardiovascular Disease
Aastrom colleagues are working every day to help people with severe, chronic cardiovascular disease realize the promise of cellular therapy. Our cellular therapy, ixmyelocel-T, draws on the human body’s own natural healing powers. Ixmyelocel-T is a patient-specific, expanded multicellular therapy produced from Aastrom’s proprietary technology.Aastrom is developing ixmyelocel-T to treat patients with severe, chronic cardiovascular diseases, including dilated cardiomyopathy (DCM).
The ixCELL-DCM Clinical Trial
The phase 2b ixCELL-DCM clinical trial will assess the efficacy and safety of ixmyelocel-T compared with placebo at 12 months post treatment for patients with ischemic dilated cardiomyopathy (DCM). The primary endpoint of the randomized, double-blind, placebo-controlled, multicenter ixCELL trial is a composite endpoint comprised of average per-patient number of all-cause deaths, all-cause hospitalizations, and unplanned outpatient or emergency department visits. We began enrolling and treating patients in the phase 2b ixCELL-DCM clinical trial in Q2 2013.
More information about ixCELL-DCM is available at ClinicalTrials.gov.